Scientists unite with AI to record dreams
Dreaming is a fascinating state where creativity runs wild, crafting vivid, cinematic scenes that can feel as real as everyday life—until you wake up and they vanish into memory or disappear from your recollection altogether.
But what if there were a way to capture, record, and playback your dreams in the real world?
At ATR Computational Neuroscience Laboratories in Kyoto, Japan, a group of scientists unveiled a complex system that uses functional magnetic resonance imaging (fMRI) and AI to 'record' people's dreams and play them back in a rough, estimated form.
The experiment focused on closely observing the brain's electrical and blood flow activity in a select group of volunteers as they slept. To achieve this, researchers combined an electroencephalogram (EEG) with an fMRI machine, allowing participants to spend several nights sleeping while their brain activity was recorded.
During the REM stage of sleep—when brain activity surges and dreams unfold—participants were gently awakened and asked to recount their dreams. This process was repeated hundreds of times, creating a rich database that linked distinct brain-scan patterns to specific dream imagery.
Using this carefully constructed database, scientists employed deep learning algorithms to attempt to reconstruct visual content while the volunteers slept.
During the tests, the system achieved approximately 60% accuracy, rising to over 70% on more specific categories like people or objects. Professor Yukiyasu Kamitani stated, 'We were able to reveal dream content from brain activity during sleep, which was consistent with the subjects' verbal reports.'
The idea of watching your dreams play out like a vintage film is undeniably captivating, but the implications for neuroscience and mental health are equally remarkable. In the future, this innovative approach could be harnessed to explore emotional and cognitive patterns in various mental health conditions, providing a non-verbal and impartial glimpse into the subconscious. As the technology advances, it holds the potential to deepen our understanding of both human consciousness and the subconscious mind.
However, while the technology is still in its early stages, the results it produces are often blurry and indistinct. Key elements such as colour, motion, narrative structure, and emotion remain largely elusive for now. Currently, dreams can only be captured in retrospect, after the subject has awakened, rather than in real-time.
Dr. Mark Stokes points out that "all of this would have to be done within individual subjects," meaning that a universal classifier capable of interpreting anyone's dreams is not feasible. In essence, a dream-reading machine is not a one-size-fits-all solution.
Nonetheless, this experiment represents a significant leap forward in the field of "oneirography," which involves the recording and documentation of dreams. As advancements in fMRI, EEG, and AI continue, the boundary between our internal mental experiences and external observation is starting to blur.
"Scientists unite with AI to record dreams" was originally created and published by Verdict, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential
The healthcare sector offers an abundance of high-growth investment opportunities. Companies leveraging artificial intelligence and genomic medicine are delivering innovative therapies with significant potential. Small-cap and under-the-radar stocks with strong growth possibilities merit closer investor attention. 10 stocks we like better than TransMedics Group › There's a strong case that healthcare is the most important sector in the stock market. These companies deliver innovative therapies and medical technologies that are often life-saving. Investors stand to benefit as healthcare leaders and emerging players address the needs of an aging global population and the rising prevalence of chronic diseases. Here are 10 under-the-radar healthcare stocks that could be great buys for your portfolio. Certara (NASDAQ: CERT) is poised to capitalize on the transformation in medicine driven by artificial intelligence (AI), providing bio-simulation software and services that accelerate drug development. The company plays a crucial role in the pharmaceutical industry. Over 90% of all novel drugs approved by the Food and Drug Administration (FDA) since 2014 have leveraged its technology. Its AI-driven solutions enhance research and development (R&D), enabling faster and more precise drug development. Certara deserves a closer look by investors seeking to tap into the AI-driven healthcare transformation. Beam Therapeutics (NASDAQ: BEAM) is a clinical-stage biotech pioneering precision-based gene editing therapies for genetic diseases, including sickle cell disease. Its innovative technology enables precise single-nucleotide DNA changes, potentially offering a safer alternative to traditional CRISPR genetic engineering. Beam has reported early success in gene correction, with its lead candidate, BEAM-101, in phase 1/2 trials for sickle cell disease. While the company still has a lot to prove, its differentiated approach and clinical progress position it for remarkable growth in the long term. Inspire Medical Systems (NYSE: INSP) develops implantable neurostimulation devices for obstructive sleep apnea, offering its FDA-approved Inspire therapy as a noninvasive alternative to CPAP machines. In its first quarter (the period ended March 31), revenue surged 23% year over year to $201 million, driven by growing U.S. adoption and new international approvals. With increasing demand for sleep apnea treatment, Inspire has a significant opportunity to capture market share. Insulet (NASDAQ: PODD) specializes in tubeless insulin pump technology. Its Omnipod system simplifies diabetes management for Type 1 and insulin-dependent Type 2 patients globally, offering convenience and improved outcomes. With a 2025 revenue growth target of 19% to 22%, the company is poised for continued expansion, particularly in underpenetrated international markets. Insulet's strong growth trajectory positions it to reward shareholders further. Krystal Biotech (NASDAQ: KRYS) focuses on rare skin diseases. Its FDA-approved gene therapy, Vyjuvek, for dystrophic epidermolysis bullosa (fragile skin that blisters easily) is expected to approach $400 million in revenue this year, solidifying its position as a best-in-class treatment. Vyjuvek's success validates Krystal's R&D, bolstering confidence in its pipeline and unlocking added market potential. LifeMD (NASDAQ: LFMD) operates a telehealth platform providing specialized virtual care in weight loss, men's health, and dermatology. A partnership with Novo Nordisk to offer Wegovy, a leading GLP-1 treatment, has driven impressive growth, with first-quarter revenue surging 49% year over year for the period ended March 31. LifeMD could expand its growing user base into a comprehensive health management ecosystem to fuel growth and solidify its telehealth leadership. Option Care Health (NASDAQ: OPCH) is the leading U.S. provider of home and alternative-site infusion services, delivering crucial therapies for chronic and acute conditions like cancer, immune deficiencies, and infections. As the healthcare industry shifts toward more personalized and cost-effective care, Option Care Health is in position to capitalize on the strong demand, with its extensive network and high-quality services. Tempus AI (NASDAQ: TEM) harnesses artificial intelligence to advance precision medicine, using its collection of clinical and molecular data from more than 40 million patients to power diagnostics in oncology, cardiology, and beyond. The company projects its revenue to climb by more than 80% this year, to about $1.3 billion. Tempus AI's scalable platform and extensive data ecosystem present substantial opportunities for expansion and impact in personalized healthcare. TransMedics Group (NASDAQ: TMDX) has revolutionized organ transplantation with its Organ Care System (OCS), the only FDA-approved device for heart, lung, and liver transplants that extends organ preservation time. The company's projected revenue growth of 30% this year underscores the strong momentum in a global expansion opportunity. Veeva Systems (NYSE: VEEV) offers cloud-based software that streamlines clinical, regulatory, and commercial processes for life sciences companies. Serving over 1,000 customers, including major pharmaceutical companies and emerging biotechs, Veeva's platform is well positioned to capitalize on the industry's increasing reliance on digital solutions for innovation and compliance. Before you buy stock in TransMedics Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and TransMedics Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $713,547!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $966,931!* Now, it's worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 177% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 Dan Victor has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Beam Therapeutics, Inspire Medical Systems, TransMedics Group, and Veeva Systems. The Motley Fool recommends Insulet, Krystal Biotech, and Novo Nordisk. The Motley Fool has a disclosure policy. 10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential was originally published by The Motley Fool
Yahoo
42 minutes ago
- Yahoo
If I Could Only Buy 1 Artificial Intelligence (AI) Stock, It Would Be This Monster "Magnificent Seven" Member Approved by Billionaires Warren Buffett and Bill Ackman
Earlier this year, Bill Ackman bought a megacap AI stock -- joining Warren Buffett as a high-profile shareholder. Ackman and Buffett are both value investors, making the timing of Ackman's purchase particularly brilliant. While the markets have been moving higher over the last several weeks, Amazon remains my top pick. 10 stocks we like better than Amazon › Bill Ackman is a billionaire investor and serves as CEO to the hedge fund Pershing Square Capital Management. Throughout the artificial intelligence (AI) revolution, Pershing Square's primary exposure to the stock market's latest megatrend has been through a position in Alphabet. Recently, however, Ackman made headlines after it was revealed that Pershing Square complemented its Alphabet position with another member of the "Magnificent Seven": Amazon (NASDAQ: AMZN). Interestingly, Amazon is one of the few technology stocks featured in Warren Buffett's portfolio at Berkshire Hathaway. Let's explore why billionaire investors like Buffett and Ackman may have taken a liking to Amazon. Moreover, I'll break down why the e-commerce and cloud computing giant is my top pick among AI stocks. Ackman and Buffett built their fortunes in different ways. Buffett is best known for building positions in globally recognized brands and holding onto these stocks over the course of many years or even decades. In addition, many of Buffett's most lucrative investments have come from companies that consistently buy back stock or pay a dividend. Lastly, Buffett generally sticks to industries such as financial services, energy, and consumer goods -- rarely exposing Berkshire to more volatile markets such as the technology sector. On the other hand, Ackman tends to be a bit more industry-agnostic compared to Buffett. Moreover, from time to time Ackman will also profit from more sophisticated trading techniques that involve derivatives. One philosophy that Buffett and Ackman do share, however, is their love for value stocks. Neither investor is known for chasing momentum or overpaying for a stock trading with a lofty valuation. The chart above benchmarks Amazon's price action relative to other megacap AI and cloud computing stocks. While each stock above faced some pressure earlier this year, Amazon's decline was more pronounced relative to its peers -- specifically throughout April. This is when Ackman pounced, buying the dip in Amazon stock during a period of notable valuation contraction. Furthermore, I think Amazon's diversified ecosystem spanning online shopping, cloud computing, subscription services, logistics, robotics, grocery delivery, streaming and entertainment, and more is another factor that played a role in the tech giant earning a spot in both Berkshire's and Pershing Square's portfolios. By operating across so many different end markets, Amazon is able to thrive under various economic conditions while also appealing to several different customer demographics. Buffett and Ackman may favor business models like this as it helps mitigate risk factors such as cyclicality, seasonality, and growth unpredictability. Given the ideas explored above, Amazon may not appear to be a traditional AI opportunity. But over the last few years, Amazon has quietly been transforming its business through a series of AI-driven investments. For starters, the company invested $8 billion into a start-up called Anthropic. Anthropic has become a key integration in Amazon Web Services (AWS), leading to sustained acceleration across revenue and profitability in the company's cloud computing business. Amazon is also deploying AI robotics throughout its fulfillment centers. This move has the potential to generate significant cost savings by bringing new levels of automation and efficiency to the company's warehouses. Moreover, while companies like IonQ or Rigetti Computing fetch the majority of attention in the quantum computing arena, Amazon is developing its own line of chipsets: Trainium, Inferentia, and Ocelot. Based on forward earnings multiples, Amazon stock isn't exactly a bargain right now. My hunch is that Amazon's diverse business and robust growth prospects may make the company appear to be more of a safe haven relative to other volatile, unpredictable opportunities in the AI realm. Even so, I don't think Amazon has experienced the same level of valuation expansion that some of its Magnificent Seven peers (e.g., Microsoft, Nvidia) have over the last couple of years. Furthermore, given how many different businesses AI stands to disrupt within the Amazon ecosystem, I think the company is uniquely positioned for sustained periods of robust growth. With that in mind, I think Amazon still has significant upside and I see a position in the stock as a superior opportunity compared to its peers. Investors with a long-run time horizon may want to consider initiating a position in Amazon stock despite its slight premium right now. Before you buy stock in Amazon, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Amazon wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $713,547!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $966,931!* Now, it's worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 177% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Adam Spatacco has positions in Alphabet, Amazon, Microsoft, and Nvidia. The Motley Fool has positions in and recommends Alphabet, Amazon, Berkshire Hathaway, Microsoft, Nvidia, and Oracle. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. If I Could Only Buy 1 Artificial Intelligence (AI) Stock, It Would Be This Monster "Magnificent Seven" Member Approved by Billionaires Warren Buffett and Bill Ackman was originally published by The Motley Fool


USA Today
an hour ago
- USA Today
Spoilers! Why 'M3GAN 2.0' is actually a 'redemption story'
Spoiler alert! We're discussing major details about the ending of 'M3GAN 2.0' (in theaters now), so beware if you haven't seen it yet. 'You wouldn't give your child cocaine. Why would you give them a smartphone?' That's the sardonic hypothetical posed by roboticist Gemma (Allison Williams) at the start of 'M3GAN 2.0,' a high-octane sequel to the 2023 hit horror comedy. When the new movie picks up, Gemma is tirelessly advocating for government oversight of artificial intelligence, after creating a bratty, pussy-bowed animatronic named M3GAN that killed four people and a dog in the original film. 'Honestly, Gemma has a point,' jokes Williams, the mother of a 3-year-old, Arlo, with actor Alexander Dreymon. 'Any time my son looks at my screen, I'm like, 'This does feel like the way people react to cocaine. This is not going to be easy to remove from his presence.' ' The first movie was an allegory about parenting and how technology is compromising the emotional human bonds that we share with one another. But in the action-packed follow-up, writer/director Gerard Johnstone wanted to explore the real-life ramifications of having M3GAN-like technology unleashed on the world. 'With the way AI was changing, and the conversation around AI was evolving, it opened up a door narratively to where we could go in the sequel,' Johnstone says. How does 'M3GAN 2.0' end? 'M3GAN 2.0' introduces a new villain in Amelia (Ivanna Sakhno), a weapons-grade automaton built by the U.S. military using M3GAN's stolen programming. But when Amelia goes rogue on a lethal mission for AI to rule the world, Gemma comes to realize that M3GAN is the only one who can stop her. Gemma reluctantly agrees to rebuild her impudent robot in a new body, and the sequel ends with an explosive showdown between Amelia and M3GAN, who nearly dies in a noble attempt to save Gemma and her niece, Cady (Violet McGraw). 'If Amelia walked out of that intact, that's a very different world we're all living in. M3GAN literally saves the world,' Williams says. 'When the first movie ends, you're like, 'Oh, she's a bad seed and I'm glad she's gone.' But by the end of this movie, you have completely different feelings about her. There's a feeling of relief when you realize she's still here, which is indicative of how much ground gets covered in this movie.' M3GAN's willingness to sacrifice herself shows real growth from the deadpanning android that audiences fell in love with two years ago. But Johnstone has always felt 'a strong empathy' towards M3GAN and never wanted to make her an outright villain. Even in the first film, 'everything she does is a result of her programming,' Johnstone says. 'As soon as she does something that Gemma disagrees with, Gemma tries to turn her off, erase her, reprogram her, and effectively kill her. So from that point of view, M3GAN does feel rightly short-changed.' M3GAN's desire to prove herself, and take the moral high ground, is 'what this movie was really about,' Johnstone adds. 'I love redemption stories.' Does 'M3GAN 2.0' set up a third movie? For Williams, part of the appeal of a sequel was getting to play with how M3GAN exists in the world, after her doll exterior was destroyed in the first movie. M3GAN is offscreen for much of this film, with only her voice inhabiting everything from a sports car to a cutesy smart home assistant. 'She's just iterating constantly, which tore through a persona that we've come to know and love,' Williams says. 'It's an extremely cool exercise in a movie like this, where we get to end the movie with a much deeper understanding of who this character is. We've now interacted with her in so many different forms, and yet we still feel the consistency of who she 'is.' That's really the fun of it.' In a way, 'she's like this digital poltergeist that's haunting them from another dimension,' Johnstone adds. 'It was a way to remind people she's more than a doll in a dress – she's an entity.' In the final scene of 'M3GAN 2.0,' we see the character living inside Gemma's computer, in a nostalgic nod to the Microsoft Word paper clip helper. (As millennials, 'our relationship with Clippy was very codependent and very complicated,' Williams quips.) But if there is a third 'M3GAN' movie, it's unlikely that you'll see her trapped in that virtual realm forever. 'M3GAN always needs to maintain a physical form,' Johnstone says. 'One aspect of AI philosophy that we address in this film is this idea of embodiment: If AI is ever going to achieve true consciousness, it has to have a physical form so it can feel anchored. So that's certainly M3GAN's point of view at the beginning of the movie: She feels that if she stays in this formless form for too long, she's going to fragment. 'M3GAN always has to be in a physical body that she recognizes – it's another reason why she won't change her face, even if it draws attention to herself. It's like, 'This is who I am and I'm not changing.' '